Nabriva Therapeutics PLC – (NASDAQ:NBRV) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 7,480,000 shares, a drop of 23.9% from the August 31st total of 9,830,000 shares. Based on an average daily volume of 5,170,000 shares, the short-interest ratio is presently 1.4 days.
Shares of NASDAQ:NBRV remained flat at $$0.53 during midday trading on Thursday. 1,022,760 shares of the stock traded hands, compared to its average volume of 4,455,590. The stock has a market cap of $1.04 billion, a PE ratio of -0.57 and a beta of 2.24. The stock’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $0.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.68 and a quick ratio of 5.20. Nabriva Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.23.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $0.25 million. Nabriva Therapeutics had a negative net margin of 932.58% and a negative return on equity of 212.02%. Sell-side analysts expect that Nabriva Therapeutics will post -0.56 earnings per share for the current year.
Several research analysts recently issued reports on the company. Northland Securities lowered their target price on Nabriva Therapeutics from $2.50 to $1.50 and set an “outperform” rating for the company in a research report on Monday, June 22nd. HC Wainwright reaffirmed a “hold” rating on shares of Nabriva Therapeutics in a research report on Friday, September 11th. BidaskClub lowered Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, August 21st. Finally, Zacks Investment Research lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.88.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: What is Cost of Debt?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.